Novo Nordisk Confirms Steady Wegovy Flow Across India with Full Shelves and High Hopes

Denmark's drug giant Novo Nordisk has officially launched its blockbuster obesity medicine Wegovy in India and has assured that there will be no supply shortage of the drug in the nation. A company official asserted, "We don't see any supply constraints and are confident of a consistent supply of the product in India," assuring the company's commitment to cashing in on the rising demand for treating obesity.

 

The launch comes when India is seeing a rising tide of obesity-related health issues, with over 254 million people overweight or obese. Wegovy, weekly injectable semaglutide, is now available in five strengths across India at an affordability level of ₹17,345 to ₹26,050 a month2.

 

Despite the global supply problem with GLP-1-based drugs like Ozempic and Wegovy, Novo Nordisk appears to have made advance arrangements for orderly launch in India. The company is leveraging its robust distribution channel and domestic manufacturing plants to maintain continuous availability.

 

Sources:Deccan Chronicle, Fortune India, Business Today